Eikon Therapeutics, INC Schedule 13G passive stakes
Filed when an investor crosses five percent without intending to seek control — the passive counterpart to a 13D.
NASDAQ
FMR LLC and Abigail P. Johnson have reported beneficial ownership of 9.2% of Eikon Therapeutics Inc.'s common stock as of June 30, 2026.
NASDAQ
Investment firm Innovation Endeavors has reported a 6.2% beneficial ownership stake in Eikon Therapeutics, Inc. as of March 31, 2026.
NASDAQ
Dr. Roger M. Perlmutter has filed a Schedule 13G reporting beneficial ownership of 5.2% of Eikon Therapeutics, Inc. common stock.
NASDAQ
FMR LLC and Abigail P. Johnson have jointly reported beneficial ownership of 7.1% of Eikon Therapeutics Inc.'s common stock as of March 31, 2026.
NASDAQ
Foresite Capital and its affiliates disclose a combined 7.7% beneficial ownership in Eikon Therapeutics, Inc. common stock.